Should I buy AbbVie stock in 2025?

Why trust HelloSafe?

At HelloSafe, our experts have been monitoring AbbVie's performance for over three years. Each month, hundreds of thousands of users across the United States rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by AbbVie.

What is AbbVie?

How much is AbbVie stock?

The price of AbbVie stock is declining this week. As of now, ABBV trades at $193.34, marking a 24-hour decrease of 0.90% (-$1.76) and a weekly drop of 6.27%. AbbVie’s market capitalization stands at $345.13 billion with an average 3-month daily volume of around 7.59 million shares. The stock currently holds a P/E ratio of 82.62, offers a solid 3.39% dividend yield, and shows a beta of 0.54, indicating lower volatility than the broader market. Despite recent downward movement, AbbVie's diversified business and steady dividends may still appeal to long-term, income-focused investors seeking stability.

Our full analysis on AbbVie stock

Having thoroughly reviewed AbbVie’s most recent financial results and analyzing the stock’s trajectory over the past three years, we deployed our proprietary algorithms to integrate key financial indicators, technical signals, evolving market data, and competitive benchmarks. With the confluence of robust sector momentum and AbbVie’s strategic pivots, a fresh perspective on its valuation surfaces. So, why might AbbVie stock once again become a strategic entry point into the U.S. healthcare sector in 2025?

Recent Performance and Market Context

AbbVie’s stock performance in the past year reflects the resilience and adaptability of its business model. Trading at $193.34 as of May 2, 2025, AbbVie has delivered an impressive 19.55% gain over the past twelve months, notably outpacing many large-cap pharmaceutical peers. Despite a modest pullback of 5.02% over the last six months and a 6.27% dip in the past week, the broader context is one of robust recovery from April’s sector-wide correction.

Positive recent catalysts have reinforced confidence. AbbVie’s Q1 2025 earnings beat expectations, with the company subsequently raising its full-year EPS guidance—a signal of both managerial confidence and underlying business health. Market receptivity to the continued growth from its immunology and neuroscience portfolios, coupled with new regulatory approvals and pipeline advancements, adds to the bullish backdrop.

The macroeconomic climate further strengthens AbbVie’s appeal. The U.S. healthcare sector’s defensive characteristics, ongoing demand for biopharmaceutical innovation, and a relatively low beta of 0.54 position the stock as an attractive anchor in diversified portfolios, especially as investors seek quality amid market volatility. The sector’s secular tailwinds—aging populations, advanced therapeutics, and expanding global healthcare access—provide a constructive backdrop for continued outperformance.

Technical Analysis

AbbVie’s current technical structure reveals an evolving bullish narrative. The Relative Strength Index (RSI) stands at 55.68, signaling neutral territory with potential room for further positives. Momentum indicators show an intriguing alignment:

• The MACD sits at -1.59 but has recently flashed a buy signal, suggesting a possible trend change and signaling early bullish momentum.
• Short-term oscillators, such as the Stochastic %K at 94.07, indicate some overbought sentiment but are consistent with strong upward price action seen after Q1 results.

Moving averages reinforce this optimism:

• The price trades above the 20-day, 100-day, and 200-day moving averages, with only the 50-day average lagging slightly above at $197.90, setting up a potential convergence and crossover in the near term.
• Technical support at $190.55 is holding firm, while resistance at $208.79 and $220.06 mark clear upside targets for renewed advances.

The overall technical rating—anchored by 14 buy signals versus 5 sell—points to a predominantly bullish structure. The recovery from the April lows, supported by healthy volume, suggests growing market conviction that AbbVie may be pivoting into a new uptrend.

Fundamental Analysis

AbbVie’s fundamentals are compelling. The company’s Q1 2025 revenue surged to $13.343 billion, up 8.4% year-over-year, with adjusted EPS climbing 6.5% to $2.46. These results exceeded consensus expectations and demonstrated operational revenue growth of 9.8% (excluding currency impacts).

This expansion is underpinned by a successful transition beyond Humira’s patent exclusivity:

• The immunology portfolio continued its meteoric ascent, with Skyrizi and Rinvoq growing by 70.5% and 57.2%, respectively, in Q1—solidifying their status as flagship products and offsetting Humira’s anticipated decline (-50.6% YoY).
• The neuroscience (+16.1% YoY) and oncology (+5.8% YoY) divisions fuel a diversified revenue stream, mitigating segment-specific risk and enhancing overall corporate stability.
• The valuation profile is noteworthy. The current TTM P/E ratio of 82.62 reflects one-off impacts, while a sharply reduced forward P/E of 15.92 presents a much more attractive picture relative to projected earnings power and sector peers. The price-to-sales and price-to-growth ratios (notably combined with robust adjusted EPS guidance and a healthy balance sheet) further validate the company’s intrinsic value proposition.

AbbVie’s capital strength—manifest in consistent, growing free cash flow—enables it to both sustain a healthy 3.39% dividend yield and invest strategically in R&D and acquisitions. The company is executing a clear, credible strategy to insulate its core business from pricing and regulatory headwinds, leveraging scale, brand equity, and a culture of relentless innovation.

Volume and Liquidity

Trading volume metrics affirm considerable market confidence. AbbVie averages over 7.5 million shares exchanged daily, underscoring deep liquidity and appealing to both institutional and retail investors. The current volume, even on consolidation days, consistently exceeds 5.8 million shares—a testament to persistent demand and efficient price discovery.

With a broad public float and a market capitalization exceeding $345 billion, the stock’s liquidity profile is optimal for active portfolio management and responsive price action. Such structural liquidity tends to underpin dynamic upward valuations, especially as the company delivers against expectations and market sentiment pivots in its favor.

Catalysts and Positive Outlook

Looking ahead, AbbVie boasts a formidable slate of growth catalysts and strategic initiatives:

• Outstanding new product performance: Skyrizi and Rinvoq’s surge not only neutralizes the Humira patent overhang but positions AbbVie as a global leader in immunology—now a $25B+ annual revenue segment.
• Pipeline progress: Regulatory wins (e.g., Rinvoq in giant cell arteritis) and recent FDA approvals, like Emblaveo for complicated intra-abdominal infections, demonstrate innovation momentum.
• Strategic partnerships: The push into obesity therapeutics via the Gubra partnership (ABBV-295), as well as collaborations with Xilio Therapeutics, open new high-potential therapeutic verticals.
• Neuroscience expansion: Growth in this division, driven by Vraylar and migraine treatments, diversifies risk and exposes the company to additional high-growth end-markets.
• ESG and operational excellence: Expansion of Allergan Medical Institute and meaningful investments in talent and process automation continue to enhance stakeholder value.

Broader sector dynamics remain supportive. Ongoing demand for innovative therapies, demographic tailwinds, and a friendlier regulatory environment for breakthrough medicines reinforce AbbVie’s multi-year growth thesis. Moreover, the company’s reliable dividend and consistently raised guidance provide additional anchors for risk-averse investors.

Investment Strategies

Several arguments coalesce to support short-, medium-, and long-term positioning:

• Short-term: Recent technical signals and the proximity to key support levels ($190.55) allow for attractive risk/reward trade setups, especially ahead of anticipated mid-year product launches and regulatory milestones.
• Medium-term: The anticipated closing of technical resistance at $208.79 and $220.06, combined with improving volume, supports accumulation strategies targeting consensus and algorithmic price objectives.
• Long-term: AbbVie’s proven pipeline execution, revenue diversification, and shareholder-friendly capital allocation position it as a durable compounder well beyond 2025. The context of a post-Humira era—now validated by product and portfolio results—confirms the potential for sustained outperformance.

Ideal entry points may arise on technical pullbacks toward major moving averages or in anticipation of key business updates—timing that could benefit both fundamentals-oriented and technically focused investors.

Is it the Right Time to Buy AbbVie?

In scrutinizing AbbVie’s current setup, several compelling strengths stand out:

• Double-digit revenue growth in key franchises and successful new product launches,
• Structural resilience illustrated by diversified revenue streams and strong dividend coverage,
• Attractive forward valuation and deep liquidity supporting efficient execution for all investor types.

With robust guidance, high-profile product catalysts, and a visible path to margin expansion, AbbVie appears well-positioned at current levels. The fundamentals justify renewed interest, while technical and strategic indicators signal the possibility of a new bullish phase in the months ahead.

For investors seeking exposure to leading U.S. biopharma, AbbVie today seems to represent an excellent opportunity to capitalize on innovation-driven growth, reliable income, and the renewed momentum of a blue-chip sector leader—delivering both stability and upside in a dynamic market environment.

How to buy AbbVie stock in United States?

Buying AbbVie stock online is both straightforward and secure when you use a regulated US brokerage platform. Today, investors can choose between two main ways to invest: purchasing shares directly (“spot buying”) to become an owner in the company, or trading Contracts for Difference (CFDs) to speculate on AbbVie’s price movements with leverage. Both methods are available through leading online brokers, making it easy for you to get started from home. Below, you’ll find a detailed comparison to help you choose the best broker for your needs.

Spot Buying

When you make a cash purchase of AbbVie stock, you’re buying physical shares that you own in your brokerage account. This method is generally preferred by longer-term investors who want to benefit from share price growth and dividends. In the US, most online brokers charge a flat fee per trade—typically around $0 to $10 per order, with major brokers now often offering commission-free trading on US stocks.

Important Example

Example: Suppose AbbVie shares are trading at $193.34. With a $1,000 investment, you could buy about 5 shares, accounting for a $5 brokerage fee. If the stock price rises by 10%, your holding would be worth $1,100.
- Result: That’s a gross gain of $100, or +10% on your invested capital.

Trading via CFDs

CFDs (Contracts for Difference) are financial instruments that let you speculate on AbbVie’s share price without actually owning the stock. CFDs allow for the use of leverage, meaning you can control a larger position with a smaller upfront investment. When trading CFDs, you typically pay a spread (the broker’s markup on the price) and, if you hold your position overnight, a small financing fee.

Important Example

Example: You open a CFD position on AbbVie stock with a $1,000 deposit and use 5x leverage, giving you exposure to $5,000 worth of shares. If AbbVie’s price rises by 8%, your position increases in value by 40% (8% × 5), giving you a profit of $400 (excluding fees and overnight charges).

Final Advice

Before investing in AbbVie via either method, it’s essential to compare fees, trading conditions, and available features across brokers (see our comprehensive broker comparison further down this page). Your choice should ultimately reflect your investment goals: buy-and-hold investors may favor cash purchases for ownership benefits and dividends, while those seeking to trade short-term price movements might prefer the flexibility of CFDs. Always invest with a trusted, regulated broker to help protect your capital.

Application

Rates & Fees

Learn More

#1

30+ million users

#1Recommended by Forbes

eToro

Rates & Fees

4.9

Discover

51% of CFD accounts lose money. You will never lose more than your investment.

#2

CFD and Indices Expert

#2

IG

Rates & Fees

4.9

Discover

74% of CFD accounts lose money. Your capital is at risk.

#3

CFD specialist

#3

Avatrade

Rates & Fees

4.8

On the broker's website

Our 7 tips for buying AbbVie stock

The latest news about AbbVie

AbbVie delivered robust Q1 2025 results, reporting an 8.4% year-over-year revenue increase and raising full-year EPS guidance. The company’s strong first-quarter results, with revenue rising to $13.34 billion and adjusted EPS up 6.5% to $2.46, exceeded market expectations and showcased AbbVie’s ability to overcome the anticipated decline in Humira sales. Management responded to this positive momentum by raising full-year 2025 adjusted EPS guidance, now projected between $12.09 and $12.29, reinforcing confidence in the sustainability of its growth trajectory in the US market.

Immunology and neuroscience portfolios are driving double-digit growth, offsetting Humira’s patent expiration impact in the United States. Newer products Skyrizi (up 70.5%) and Rinvoq (up 57.2%) demonstrated exceptional performance in the critical immunology segment, crucial for the US where Humira’s patent protections have expired. Neuroscience sales also grew 16.1%, further diversifying US revenue streams and highlighting AbbVie's resilience and adaptability in the local biopharmaceutical landscape.

Recent FDA approval of Emblaveo and expanded US aesthetics training centers signal continued innovation and local investment. The US FDA's recent approval of Emblaveo for complicated intra-abdominal infections adds to AbbVie’s pipeline of new therapies, reinforcing the company's commitment to regulatory excellence and US market expansion. The establishment of additional Allergan Medical Institute training centers across the US enhances its presence in medical aesthetics education, potentially improving competitiveness and customer loyalty among US healthcare professionals.

AbbVie’s technical indicators suggest a neutral to bullish short-term outlook, supported by resilient demand and upward momentum. While the stock saw a one-week decline of 6.27%, technical analysis points to a neutral-to-bullish bias, with the price trading above most key moving averages and momentum building following a recovery from April lows. Strong buy signals from moving averages and neutral RSI reinforce the outlook that recent weakness may be temporary, especially as investor sentiment in the US market remains constructive.

The company’s dividend yield remains attractive, with reliable payouts appealing to US-based income investors. At a 3.39% yield and an annual dividend of $6.56 per share, AbbVie continues to deliver steady returns, a key consideration for US investors seeking both income and stability. AbbVie's consistent record of dividend growth, combined with qualified dividend tax treatment in the United States and eligibility for tax-advantaged accounts like IRAs and 401(k)s, further enhances its positioning among domestic income-oriented portfolios.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.